^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    VENTANA DLL3 (SP347) Assay

    Company:
    Roche
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    3d
    1438-0011: A study in people with advanced extrapulmonary neuroendocrine cancer to compare obrixtamig plus carboplatin and etoposide treatment with standard chemotherapy. (2025-523869-22-00)
    P2/3, N=74, Not yet recruiting, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
    New P2/3 trial
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    VENTANA DLL3 (SP347) Assay
    |
    carboplatin • etoposide IV • obrixtamig (BI 764532)
    3d
    1438-0012: DAREON-Lung-1: A study in people with advanced small cell lung cancer to compare obrixtamig plus atezolizumab, carboplatin, and etoposide treatment with standard chemotherapy. (2025-520565-51-00)
    P2/3, N=105, Not yet recruiting, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
    New P2/3 trial
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    VENTANA DLL3 (SP347) Assay
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • obrixtamig (BI 764532) • Actemra IV (tocilizumab)
    24d
    A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy (clinicaltrials.gov)
    P3, N=390, Not yet recruiting, Boehringer Ingelheim
    New P3 trial
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    VENTANA DLL3 (SP347) Assay
    |
    carboplatin • etoposide IV • obrixtamig (BI 764532)
    26d
    DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy (clinicaltrials.gov)
    P3, N=670, Recruiting, Boehringer Ingelheim | Not yet recruiting --> Recruiting
    Enrollment open
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    VENTANA DLL3 (SP347) Assay
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • obrixtamig (BI 764532)
    1m
    DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy (clinicaltrials.gov)
    P3, N=670, Not yet recruiting, Boehringer Ingelheim | Trial completion date: Apr 2029 --> Jul 2029
    Trial completion date
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    VENTANA DLL3 (SP347) Assay
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • obrixtamig (BI 764532)
    2ms
    DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy (clinicaltrials.gov)
    P3, N=670, Not yet recruiting, Boehringer Ingelheim
    New P3 trial
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    VENTANA DLL3 (SP347) Assay
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • obrixtamig (BI 764532)
    5ms
    Multi-center Assessment of DLL3 Expression by Immunohistochemistry in Medullary Thyroid Carcinoma. (PubMed, Endocr Pathol)
    Our findings indicate that DLL3 is frequently expressed in MTC and its high expression identifies tumors with aggressive pathological characteristics and poor clinical outcomes. These results support DLL3 as a potential prognostic biomarker and therapeutic target in MTC, highlighting the need for further validation and integration into clinical trials of DLL3-directed therapies.
    Retrospective data • Journal
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    VENTANA DLL3 (SP347) Assay
    6ms
    DLL3 Immunohistochemical Expression in Neuroendocrine-Transformed EGFR-Mutant Lung Cancer and Two Cases of Tarlatamab Therapy. (PubMed, JTO Clin Res Rep)
    Tarlatamab appeared effective when added to osimertinib. Further analysis of the combination of bispecific DLL3 T-cell engager and EGFR tyrosine kinase inhibitor is warranted to confirm these findings.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    TP53 mutation • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • RB1 mutation • DLL3 expression
    |
    VENTANA DLL3 (SP347) Assay
    |
    Tagrisso (osimertinib) • Imdelltra (tarlatamab-dlle)
    almost2years
    DLL3 Expression in Early-Stage SCLC: Comparative Analysis of IHC and mRNA ISH in Tumor and Lymph Nodes (IASLC-WCLC 2024)
    Both IHC and mRNA ISH showed significant correlation in tumors and lymph node metastasis. An observed trend suggested improved survival in patients with no DLL3 expression.
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression • DLL3 positive
    |
    VENTANA DLL3 (SP347) Assay
    almost2years
    Expression profile differences according to grade in medullary thyroid carcinoma (ECP 2024)
    High-grade and low-grade MTC have different expression profiles. DLL3 should be explored as a predictor of aggressive disease and poor outcome in MTC.
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • DLL3 (Delta Like Canonical Notch Ligand 3) • ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1)
    |
    MYC expression • DLL3 expression • TP53 expression • DLL3 positive
    |
    VENTANA DLL3 (SP347) Assay
    almost2years
    DLL3 Expression In Early—Stage SCLC: Comparative Analysis Of IHC and mRNA ISH (LUNG-SPORE 2024)
    "Tarlatamab, targeting DLL3 and CD3, showed a 40% response rate in previously treated patients... In 248 early-stage SCLC, positivity for DLL3 was 58% with IHC and 87% with mRNA ISH. A trend for improved survival in patients with no DLL3 expression was observed. Future studies on DLL3 might improve SCLC treatment SCLC."
    VENTANA DLL3 (SP347) Assay
    |
    Imdelltra (tarlatamab-dlle)
    2years
    Phase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC). (ASCO 2024)
    Findings from this phase 1 study of tarlatamab in pts with NEPC demonstrated manageable safety with encouraging anti-tumor activity in DLL3 expressing NEPC. Further investigation is ongoing.
    P1 data • IO biomarker
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    VENTANA DLL3 (SP347) Assay
    |
    Imdelltra (tarlatamab-dlle)